Trial Profile

A phase 3 Trial of IMU-838 in Primary Progressive Multiple Sclerosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2026 New trial record
13 Feb 2026 According to an Immunic media release, the company is working towards initiation of a phase 3 clinical program, which is expected later this year and estimated to take approximately 3.5 to 4 years to complete.
13 Feb 2026 According to an Immunic media release, the company announced the pricing of a private placement with gross proceeds of up to USD 400 million, priced at-the-market under Nasdaq rules. The proceeds from this financing are expected to support the completion of the Phase 3 ENSURE trials in relapsing multiple sclerosis, the initiation of a Phase 3 trial in primary progressive multiple sclerosis, and the transition into a commercial organization.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com